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Dear Editor, 
 
We agree with TLID that any prioritisation exercise inevitably leads to a decrease in 
emphasis on pathogens that are not on the list.(1)Restricting the list to promote research on 
antibacterial agents may be justifiable, however, Mycobacterium tuberculosis is a 
bacterium. It is insufficient to state that drug resistant tuberculosis “is already a globally 
established priority for which innovative new treatments are urgently needed”. For 
example, multi-drug resistant Gram negative pathogens are a priority area for several major 
funders in a way that drug resistant tuberculosis is yet to achieve.(2)(3)(4) This is partly a 
combination of the limited options for many MDR gram negative pathogens which often 
affect immunocompromised patients with adverse, and often fatal, outcomes even in the 
most resourced settings. That tuberculosis disproportionately affects deprived populations, 
has remained a key reason for market failure to develop novel antimicrobials. The discovery 
of new antibiotics for gram negative pathogens is a critical priority for mankind, but this 
should not lead to the inadvertent relegation of tuberculosis research.  
 
The focus on new antibiotics, while laudable, also underplays the importance of novel 
interventions beyond antibiotics – research on preventive and alternative curative non-
antibiotic treatment options should be encouraged.(5)  
 
Great progress has been made in successfully presenting AMR as a major global health 
challenge, however, we are unlikely to tackle this threat with a list alone until all relevant 
elements of society identify the current situation as a critical issue. Without a major societal 
shift, the necessary capital to address the economic, scientific and regulatory factors to 
contribute to the discovery of new drugs and preventive measures will continue to elude us. 
The goal of bringing all stakeholders together will not be achieved by excluding multi-drug 
resistant tuberculosis which is estimated to cause 250,000 deaths annually.(6) 
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